Year None20202019201820172014 Nov 24, 2020 PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference Nov 23, 2020 PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53 Nov 13, 2020 PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights Oct 13, 2020 PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation Sep 29, 2020 PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares Sep 24, 2020 PMV Pharma Announces Pricing of Initial Public Offering Sep 08, 2020 PMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel Aug 03, 2020 PMV Pharma Closes $70 Million in Series D Financing; Dr. Rich Heyman appointed as Chair of the Board of Directors of PMV Pharma
